| Temozolomide Basic information |
| Anticancer drugs Pharmacokinetics Toxicological effects The treatment of recurrent glioblastoma multiforme tumor Clinical evaluation Patent No |
| Product Name: | Temozolomide |
| Synonyms: | 4-methyl-5-oxo-2,3,4,6,8-pentazabicyclo [4.3.0] nona-2,7,9-triene-9-carboxamide;TEMOZOLOMIDE;methazolastone;nsc362856;temodar;Temozolamide;Temozolimide;3,4-Dihydro-3-methyl-4-oxoimidazo [5,1-d] -1,2,3,5-tetrazin-4(3H)-one, Methazolastone, M&B 39831, Temodal, Temodar, |
| CAS: | 85622-93-1 |
| MF: | C6H6N6O2 |
| MW: | 194.15 |
| EINECS: | 630-358-9 |
| Product Categories: | TEMODAR;Displays antitumor activity.;Bases & Related Reagents;Heterocycles;Nucleotides;API;Active Pharmaceutical Ingredients;Antineoplastic;Intermediates & Fine Chemicals;Pharmaceuticals;Antitumour;Inhibitors;85622-93-1 |
| Mol File: | 85622-93-1.mol |
|
|
| Temozolomide Chemical Properties |
| Melting point | 212°C dec. |
| Boiling point | 526.6±42.0 °C(Predicted) |
| density | 1.97±0.1 g/cm3(Predicted) |
| storage temp. | 2-8°C |
| solubility | DMSO: soluble10mg/mL, clear |
| pka | 14.77±0.20(Predicted) |
| form | powder |
| color | white to light brown |
| Merck | 14,9139 |
| Stability: | Stable for 2 years as supplied. Solutions in DMSO may be stored at -20° for up to 3 months. |
| InChIKey | BPEGJWRSRHCHSN-UHFFFAOYSA-N |
| CAS DataBase Reference | 85622-93-1(CAS DataBase Reference) |
| Safety Information |
| Hazard Codes | T,Xi |
| Risk Statements | 45-46-60-61-22-36/37/38 |
| Safety Statements | 24/25-45-36/37-26-53-36 |
| WGK Germany | 3 |
| RTECS | NJ5927050 |
| HS Code | 29339900 |